Opioid Addiction Treatment: Why Detox Alone Is the Dangerous Choice

Opioid use disorder is the one addiction where the medication is the treatment, and everything else is built around it.

Three medications are approved by the FDA: methadone, buprenorphine and naltrexone. They are not a crutch, a substitute addiction, or a lesser form of recovery. They are the intervention with the strongest effect on whether someone lives.

The numbers are unusually clear for this field. Federal research associates methadone with 58% lower odds of dying from overdose and buprenorphine with 52% lower odds. A separate study following people for twelve months found overdose deaths down 59% with methadone and 38% with buprenorphine.

Which leads directly to the thing most people are not told, and the reason this page opens the way it does: getting through withdrawal is not the achievement it feels like. Without a medication to follow, it leaves someone with the same craving and far less tolerance than they had a week earlier — and that combination is what kills people.

This is counterintuitive enough that it is worth stating slowly.

Opioid tolerance falls within days of stopping. Someone using daily builds a tolerance that lets them take doses which would seriously harm a person without one. Stop for a week and much of that protection is gone. The craving, however, does not fall on the same schedule — it commonly outlasts the physical symptoms by months.

So the week after a successful detox contains a specific, well-documented hazard: a person who returns to their previous dose is taking a quantity their body can no longer handle. Clinical guidance is explicit that anyone who has withdrawn from opioids must be warned about reduced tolerance, and rapid tapers in particular are associated with increased risk of fatal overdose.

Put next to the outcome data, the case becomes hard to argue with. Short-term abstinence after medically supervised withdrawal alone runs at roughly 20 to 40 per cent, and detox without a subsequent medication is associated with an increased risk of fatal overdose. The intervention that feels like the decisive step is, on its own, the one that raises the danger.

None of this is an argument against detox. It is an argument against detox as a standalone plan. Where withdrawal management is clinically needed, it should be the first day of a treatment plan that already has a medication decision in it — not an achievement that a person is then congratulated for and sent home from.

All three are approved by the FDA, all three have evidence behind them, and the choice between them is clinical rather than moral.

Addiction medicine rarely produces numbers this clean, which is why they are worth setting out rather than summarising.

On mortality. Federal research associates methadone with a 58% reduction in the odds of overdose death and buprenorphine with 52%. A twelve-month follow-up study found overdose deaths reduced by 59% and 38% respectively. Both medications also reduce all-cause mortality, withdrawal symptoms, craving, and transmission of HIV and other infections.

On withdrawal management alone. Between 20 and 40 per cent maintain short-term abstinence. Detox without a subsequent medication is associated with an increased — not reduced — risk of fatal overdose.

On timing. Risk of death is highest in the first four weeks of treatment and the four weeks after treatment ends. Both are transition points, and both are periods where tolerance and structure are changing faster than habits are.

The practical reading of all of this is narrow. Ask about medication at the first appointment. If a programme does not raise it, raise it yourself, and if a programme discourages it, that is information about the programme rather than about the medication.

Knowing the shape of it removes some of the fear, and knowing where the real danger sits removes considerably more.

This is the most-asked question in the whole cluster, and it deserves a precise answer rather than a reassuring one.

Opioid withdrawal is not usually directly fatal in the way alcohol or benzodiazepine withdrawal can be. That distinction is real and worth knowing: someone stopping alcohol abruptly can have seizures and die from the withdrawal itself; that is not the typical pattern with opioids.

But "not usually directly fatal" is not the same as safe, and three qualifications matter. Fluid loss from severe vomiting and diarrhoea can cause dangerous dehydration and electrolyte disturbance, particularly in someone with a heart condition or who is already unwell. Vomiting while sedated or unconscious carries an aspiration risk. And the period afterwards is the genuine killer, for the tolerance reason set out above.

There is one situation where the answer changes completely. If someone is dependent on opioids and alcohol or benzodiazepines together, the withdrawal risk is governed by the more dangerous of the two, and that is a medical emergency rather than a difficult week. Combined dependence is common and frequently under-reported at assessment.

The honest summary: withdrawal is unlikely to kill you; going through it without a plan for what follows might.

Almost every piece of received wisdom about opioids was formed before fentanyl dominated the illicit supply, and several of them no longer hold.

Potency and unpredictability. Fentanyl is far more potent by weight than heroin, and it is not evenly distributed through a supply that was never manufactured to a standard. Two doses from the same source can differ substantially. Judging a dose by experience — the skill people rely on — stopped being reliable.

It is in things that are not sold as opioids. Counterfeit pills pressed to look like prescription medication routinely contain fentanyl, which means someone who believes they are taking a known pharmaceutical may have no opioid tolerance at all. This is how people with no history of opioid use die of opioid overdose.

Withdrawal behaves differently. Clinicians report that fentanyl's tissue distribution can make withdrawal onset and duration less predictable than with heroin, and that starting buprenorphine requires more care to avoid precipitating withdrawal. This is a practical argument for medical supervision rather than a DIY taper.

Adulterants have arrived alongside it. Xylazine — a veterinary sedative, not an opioid — is increasingly found in the supply. It does not respond to naloxone, though naloxone should still be given because opioids are usually present too, and it is associated with severe wounds that need medical attention in their own right.

The practical translation for a family: assume the supply is contaminated, keep naloxone in the house, and treat "they only take pills" as no reassurance at all.

This is the shortest section on the page and possibly the most useful.

Naloxone reverses an opioid overdose. It is available without a prescription in every US state, it is inexpensive, it is given as a nasal spray, and it is harmless if administered to someone who turns out not to be overdosing. There is no scenario in which having it makes things worse.

Three practical points. Keep it where it would actually be found — a bathroom cabinet or bedside drawer, not a car boot. Tell someone else it is there, because the person overdosing cannot administer it. And call 911 anyway: naloxone wears off faster than many opioids, so someone can be revived and then deteriorate again.

One thing worth naming, because it stops people acting: keeping naloxone is not an expectation of failure. Households keep fire extinguishers without expecting a fire. The families who most regret not having it are the ones who assumed things were going well — which, given how the highest-risk weeks line up with feeling better, is exactly the wrong assumption.

The honest answer is longer than most people want to hear, and the honesty matters because unrealistic expectations are themselves a risk factor.

There is no fixed course. Medication for opioid use disorder is generally continued for as long as it is providing benefit, which for many people is measured in years rather than weeks. A programme presenting a fixed short course, or framing medication as something to be got off as quickly as possible, is not describing standard practice.

The comparison that helps is with other long-term conditions. Nobody asks when a person will stop treatment for hypertension. Opioid use disorder involves lasting changes to the systems that govern reward and stress, and continuing a medication that stabilises them is not a failure to recover — it is the recovery.

Stopping is a clinical decision, made deliberately. Where someone does want to come off, it is done as a planned taper with support in place and a clear understanding that tolerance falls as the dose does. The dangerous version is stopping abruptly because of a change in circumstances, a lapse in prescribing, a move, or a programme that ends.

Which produces a specific question worth asking any provider at the outset: what happens to my prescription if I move, change job, lose coverage or the programme closes? Continuity is the whole point of this level of treatment, and an interruption is not an administrative inconvenience — it is a return to the highest-risk state.

The levels are the same continuum as for any substance, with one difference that overrides the rest: at every level, the medication question comes first.

Medically supervised withdrawal manages the acute phase. It is appropriate where it is genuinely indicated and dangerous as a plan on its own — see above.

Residential treatment provides a controlled environment around the clock, which matters most where the home environment is unsafe or where combined dependence is involved. Ask directly whether the facility continues medication during the stay: some historically have not, and that gap is where relapse and overdose concentrate after discharge.

Day treatment and intensive outpatient deliver structure while someone sleeps at home. For opioids specifically, they work well alongside stable medication and much less well as a substitute for it. Our comparison of the two levels covers how the choice is made.

Outpatient care is where most long-term medication treatment actually happens, and where most of the time is spent. It is the least dramatic level and the one that determines the outcome.

Opioid treatment is covered by insurance on the same parity basis as any other addiction treatment, and medication is generally covered as a pharmacy benefit rather than as part of a programme fee — which is worth checking separately. Our guide to insurance coverage sets out how to verify a specific plan before committing.

Two points specific to opioids. Medication is the least expensive component of effective treatment and the one with the strongest evidence, which makes it poor economy to skip. And where cost genuinely constrains the plan, office-based buprenorphine with outpatient support is far cheaper than residential care and is not a lesser intervention on the measure that matters most.

Families arrive at this page frightened, often after a long period of being managed, and usually with a plan that centres on getting the person to stop. A few things reorder the priorities usefully.

Get naloxone today, before any other conversation happens. It requires no cooperation from the person using and no agreement about anything. It is the single highest-value action available to you, and it is available this afternoon.

Aim the conversation at medication, not at abstinence. "Will you stop?" invites a promise that neither of you can rely on. "Will you see someone about buprenorphine?" is a specific, achievable request with a real effect on survival — and it does not require the person to be ready to quit everything first.

Do not push for an unsupported detox. It is the intervention families most often demand and the one that raises overdose risk. If the person has just come out of detox, incarceration or hospital, treat the following weeks as the highest-risk period rather than the moment to relax.

Expect the first conversation to fail, and hold the boundary about safety separately from the boundary about use. You can decline to fund use while still keeping naloxone in the house and the door open. Those are not contradictory positions, and conflating them costs people their lives.

Five questions that separate a programme practising current standards from one that has not updated since the medications became first-line.

Everything above describes how opioid use disorder is generally treated. It is not an assessment of you or of anyone you love, and it cannot replace one. Which medication is appropriate, at what dose, and how to start it safely are decisions made by a clinician who has taken a history.

If opioid use is combined with alcohol or benzodiazepines, do not attempt withdrawal without medical advice. The combination carries risks that opioids alone do not, and withdrawal from alcohol or benzodiazepines can cause seizures.

If someone is unresponsive, breathing slowly or not at all, or has blue lips or fingertips, give naloxone and call 911 immediately. For a suicidal or mental health crisis in the US, call or text 988. For free, confidential treatment referral around the clock, the SAMHSA National Helpline is 1-800-662-HELP (4357).